Balloon- Versus Self-Expanding Transcatheter Valves for Failed Small Surgical Aortic Bioprostheses: 3-Year Results of the LYTEN Trial


Por: Cepas-Guillén, P, Abbas, AE, Serra, V, Vilalta, V, Nombela-Franco, L, Regueiro, A, Al-Azizi, KM, Iskander, A, Conradi, L, Forcillo, J, Lilly, S, Calabuig, A, Fernandez-Nofrerias, E, Mohammadi, S, Giuliani, C, Pelletier-Beaumont, E, Pibarot, P and Rodés-Cabau, J

Publicada: 1 mar 2026
Resumen:
BACKGROUND:Data comparing valve systems in the valve-in-valve transcatheter aortic valve replacement (TAVR) field have been obtained from retrospective studies. This prespecified secondary analysis of the LYTEN randomized trial (Comparison of the Balloon-Expandable Edwards Valve and Self-Expandable CoreValve Evolut R or Evolut PRO System for the Treatment of Small, Severely Dysfunctional Surgical Aortic Bioprostheses) aims to compare the 3-year hemodynamic performance and clinical outcomes between balloon-expandable valves (BEV) SAPIEN 3/ULTRA (Edwards Lifesciences) and self-expanding valves (SEV) Evolut R/PRO/PRO+ (Medtronic) in valve-in-valve TAVR. METHODS:Patients with a failed small (<= 23 mm) surgical valve undergoing valve-in-valve TAVR were randomized to receive a SEV or a BEV. Patients had a clinical and valve hemodynamic (Doppler echocardiography) evaluation at 3-year follow-up. Study outcomes were defined according to VARC (Valve Academic Research Consortium)-2/VARC-3 criteria. Intended performance of the valve was defined as mean gradient <20 mm Hg, peak velocity <3 m/s, Doppler velocity index >= 0.25, and less than moderate aortic regurgitation. RESULTS:Ninety-eight patients underwent TAVR (46 BEV [SAPIEN 3/ULTRA], 52 SEV [Evolut R-PRO-PRO+]). At 3 years, patients receiving a SEV had a higher rate of intended valve performance (BEV: 27.6% versus SEV: 82.4%; P<0.001), with lower mean gradients (BEV: 20 +/- 9 versus SEV: 13 +/- 9 mm Hg; P=0.002), and larger indexed effective orifice area (BEV: 0.69 +/- 0.27 versus SEV: 0.93 +/- 0.32 cm2/m2; P=0.002). The rate of moderate aortic regurgitation was 0% in the BEV group versus 2.9% in the SEV group (P=0.582). Functional status and quality of life improved similarly in both groups. No differences were observed in the composite end point of death, stroke, or heart failure-related hospitalization (BEV: 32.6% versus SEV: 25.5%; P=0.489). Mortality was also not statistically different between groups (BEV: 23.3% versus SEV: 15.7%; P=0.375). No significant differences were observed in other adverse events.CONCLUSIONS:In patients undergoing valve-in-valve TAVR for failed small aortic bioprostheses, SEV demonstrated a superior valve hemodynamic performance at 3-year follow-up, with similar clinical outcomes and functional improvement compared with BEV.REGISTRATION:URL: https://www.clinicaltrials.gov; Unique identifier: NCT03520101.

Filiaciones:
Cepas-Guillén, P:
 Laval Univ, Quebec Heart & Lung Inst, Cardiol Dept, Quebec City, PQ, Canada

 Univ Barcelona, Hosp Clin Barcelona, Inst Invest Biomed August Pi i Sunyer, Clin Cardiovasc Inst,Cardiol Dept, Barcelona, Spain

Abbas, AE:
 William Beaumont Univ Hosp, Cardiol Dept, Corewell Hlth East, Royal Oak, MI USA

Serra, V:
 Hosp Univ Vall dHebron, Cardiol Dept, Barcelona, Spain

:
 Hosp Univ Germans Trias i Pujol, Badalona, Spain

Nombela-Franco, L:
 Hosp Clin San Carlos, Inst Invest Sanitaria, Cardiovasc Inst, Cardiol Dept,IdISSC, Madrid, Spain

Regueiro, A:
 Univ Barcelona, Hosp Clin Barcelona, Inst Invest Biomed August Pi i Sunyer, Clin Cardiovasc Inst,Cardiol Dept, Barcelona, Spain

Al-Azizi, KM:
 Baylor Scott & White Heart Hosp Plano, Cardiol Dept, Plano, TX USA

Iskander, A:
 St Josephs Hlth SJH Cardiol Associates, Cardiol Dept, Syracuse, NY USA

Conradi, L:
 Univ Heart & Vasc Ctr, Cardiol Dept, Hamburg, Germany

Forcillo, J:
 Ctr Hosp Univ Montreal, Cardiol Dept, Montreal, PQ, Canada

Lilly, S:
 Ohio State Univ, Richard M Ross Hosp, Cardiol Dept, Heart & Vasc Res Org, Columbus, OH USA

Calabuig, A:
 Hosp Univ Vall dHebron, Cardiol Dept, Barcelona, Spain

Fernandez-Nofrerias, E:
 Hosp Univ Germans Trias i Pujol, Badalona, Spain

Mohammadi, S:
 Laval Univ, Quebec Heart & Lung Inst, Cardiol Dept, Quebec City, PQ, Canada

Giuliani, C:
 Laval Univ, Quebec Heart & Lung Inst, Cardiol Dept, Quebec City, PQ, Canada

Pelletier-Beaumont, E:
 Laval Univ, Quebec Heart & Lung Inst, Cardiol Dept, Quebec City, PQ, Canada

Pibarot, P:
 Laval Univ, Quebec Heart & Lung Inst, Cardiol Dept, Quebec City, PQ, Canada

Rodés-Cabau, J:
 Laval Univ, Quebec Heart & Lung Inst, Cardiol Dept, Quebec City, PQ, Canada

 Univ Barcelona, Hosp Clin Barcelona, Inst Invest Biomed August Pi i Sunyer, Clin Cardiovasc Inst,Cardiol Dept, Barcelona, Spain
ISSN: 19417640





CIRCULATION-CARDIOVASCULAR INTERVENTIONS
Editorial
Lippincott Williams & Wilkins Ltd., TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA, Estados Unidos America
Tipo de documento: Article
Volumen: 19 Número: 3
Páginas:
WOS Id: 001715444600004
ID de PubMed: 41623058

MÉTRICAS